# NDAs: Impurities in Drug Substances - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/ndas-impurities-in-drug-substances/9a9aed41-ecdb-4d76-ae37-eed05ef236c6

> FDA guidance document: NDAs: Impurities in Drug Substances. Issue date: February 01, 2000. Get complete insights and analysis.

---

## Details

- Title: NDAs: Impurities in Drug Substances
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2000-02-01
- Last Changed: 2022-04-28
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-1998-D-0277">FDA-1998-D-0277</a>

## Related Documents

- [Levothyroxine Sodium Tablets - In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing](https://www.globalkeysolutions.net/guidances/guidance-document/levothyroxine-sodium-tablets-in-vivo-pharmacokinetic-and-bioavailability-studies-and-in-vitro-dissolution-testing/74b4ee28-e27e-400e-8b87-ba8701d4ea31)
- [Alternate Source of the Active Pharmaceutical Ingredient in Pending ANDAs:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/alternate-source-of-the-active-pharmaceutical-ingredient-in-pending-andas-guidance-for-industry/8a3da1bc-1ebb-48aa-a3ea-7662562c4370)
- [Drug Master Files for Bulk Antibiotic Drug Substances:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/drug-master-files-for-bulk-antibiotic-drug-substances-guidance-for-industry/2638fcb2-869c-4214-8f7d-6403c9f7b75e)